Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics-Reference-Cited by-同舟云学术

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics

Published:2020-03-10 Issue:8 Volume:24 Page:4668-4676
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Kellner Fabienne¹,Keil Andreas¹,Schindler Katrin¹,Tschongov Todor¹,Hünninger Kerstin²,Loercher Hannah¹,Rhein Peter³,Böhmer Sylvia‐Annette¹,Böhmer Frank‐D.¹,Müller Jörg P.¹^ORCID

Affiliation:

1. Institute for Molecular Cell Biology Center for Molecular Biomedicine Jena University Hospital Jena Germany

2. Fungal Septomics Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute Jena Germany

3. Luminex B.V. ‘s‐Hertogenbosch The Netherlands

Funder

Deutsche Forschungsgemeinschaft

Deutsche Krebshilfe

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.15132

Reference39 articles.

1. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases

2. Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles

3. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival

4. Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia

5. FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML;Molecular Biology Reports;2024-04-16

2. Engineered Flt3L Drives Tolerogenic State to Attenuate Anti-drug Antibody Responses;2024-03-27

3. BRCC36 associates with FLT3‐ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia;Cancer Science;2024-01-30

4. FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review;Critical Reviews in Oncology/Hematology;2023-11

5. Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD;Frontiers in Oncology;2022-11-14